NCT03126591View on ClinicalTrials.gov

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

May 6, 2021

Study Completion Date

February 21, 2023

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Olaratumab

Administered IV

DRUG

Pembrolizumab (KEYTRUDA®)

Administered IV

Trial Locations (6)

2730

Herlev and Gentofte Hospital, Herlev

3000

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

10065

Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh Medical Center, Pittsburgh

94805

Gustave Roussy, Villejuif

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT03126591 - A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter